Axogen Inc vs Kyndryl Holdings Inc — how do they compare? Axogen Inc trades at $48.35 (market cap $2.59B), while Kyndryl Holdings Inc trades at $13.26 (market cap $2.97B). The key difference: Axogen Inc and Kyndryl Holdings Inc are close in size by market cap, and Axogen Inc is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AXGN | KD | |
|---|---|---|
Market Cap | $2.59B | $2.97B |
Sector | Technology | Technology |
52-Week High | $48.48 | $33.14 |
52-Week Low | $14.16 | $10.59 |
Enterprise Value | $2.50B | $5.79B |
Signals from Pluang's Aura AI — not financial advice
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →